Jingyi Li

US Patent:

20220177858, Jun 9, 2022

Filed:

Apr 17, 2020

Appl. No.:

17/604722

Inventors:

- San Diego CA, US
Russell Scott Komor - San Diego CA, US
Jingyi Li - San Diego CA, US

International Classification:

C12N 9/10
C12N 15/52
C12N 1/20
C12P 7/22

Abstract:

Described herein are non-natural olivetol synthase (OLS) variants, nucleic acids, engineered cells, method s for preparing cannabinoids, and compositions thereof. The non-natural olivetol OLS variants form desired cannabinoid precursor and products at increased rates, have higher affinity for pathway substrates, and/or byproducts are formed in lower amounts in their presence, as compared to wild type OLS. The OLS variants can be used to form linear polyketides, and can be expressed in an engineered cell having a pathway to form cannabinoids, which include CBGA, its analogs and derivatives. CBGA can be used for the preparation of cannabigerol (CBG), which can be used in therapeutic compositions.

US Patent:

20230094365, Mar 30, 2023

Filed:

Apr 29, 2022

Appl. No.:

17/733404

Inventors:

- San Diego CA, US
Brandon Chen - San Diego CA, US
Jingyi Li - San Diego CA, US
Shawn Bachan - San Diego CA, US

International Classification:

C07D 471/22
C07D 487/14
C07D 487/22

Abstract:

This invention relates to compounds and compositions useful as inhibitors of PIM kinases. Also provided are methods of synthesis and methods of use of PIM inhibitors in treating individuals suffering from cancerous malignancies.

US Patent:

20200354692, Nov 12, 2020

Filed:

Feb 17, 2020

Appl. No.:

16/792592

Inventors:

- San Diego CA, US
Michael Patrick Kuchinskas - San Diego CA, US
Jingyi Li - San Diego CA, US
Harish Nagarajan - San Diego CA, US
Priti Pharkya - San Diego CA, US

International Classification:

C12N 9/04
C12P 7/24
C12P 7/18

Abstract:

Described herein are non-natural NAD-dependent alcohol dehydrogenases (ADHs) capable of at least two fold greater conversion of methanol or ethanol to formaldehyde or acetaldehyde, respectively, as compared to its unmodified counterpart. Nucleic acids encoding the non-natural alcohol dehydrogenases, as well as expression constructs including the nucleic acids, and engineered cells comprising the nucleic acids or expression constructs are described. Also described are engineered cells expressing a non-natural NAD-dependent alcohol dehydrogenase, optionally include one or more additional metabolic pathway transgene(s), methanol metabolic pathway genes, target product pathway genes, cell culture compositions including the cells, methods for promoting production of the target product or intermediate thereof from the cells, compositions including the target product or intermediate, and products made from the target product or intermediate.

US Patent:

20200331914, Oct 22, 2020

Filed:

Nov 5, 2018

Appl. No.:

16/761715

Inventors:

- San Diego CA, US
Brandon Chen - San Diego CA, US
Jingyi Li - San Diego CA, US
Shawn Bachan - San Diego CA, US

International Classification:

C07D 471/22
C07D 487/14
C07D 487/22

Abstract:

This application relates to compounds of formulae (I) and (II) and compositions thereof useful as inhibitors of PIM kinases. Also provided are methods of synthesis and methods of use of PIM inhibitors in treating individuals suffering from cancerous malignancies.

US Patent:

20190085303, Mar 21, 2019

Filed:

Oct 27, 2016

Appl. No.:

15/771973

Inventors:

- San Diego CA, US
Jingyi Li - San Diego CA, US
Joseph R. Warner - San Diego CA, US
Priti Pharkya - San Diego CA, US

International Classification:

C12N 9/04
C12N 9/88
C12N 9/90
C12N 9/10
C12P 7/24

Abstract:

Described herein are fusion proteins including methanol dehydrogenase (MeDH) and at least one other polypeptide such as 3-hexulose-6-phosphate dehydrogenase (HPS) or 6-phospho-3-hexuloisomerase (PHI), such as DHAS synthase or fructose-6-Phosphate aldolase or such as DHA synthase or DHA kinase. In a localized manner, the fusion protein can promote the conversion of methanol to formaldehyde and then to a ketose phosphate such as hexulose 6-phosphate or then to DHA and G3P. When expressed in cells, the fusion proteins can promote methanol uptake and rapid conversion to the ketose phosphate or to the DHA and D3P, which in turn can be used in a pathway for the production of a desired bioproduct. Beneficially, the rapid conversion to the ketose phosphate or to the DHA and G3P can avoid the undesirable accumulation of formaldehyde in the cell. Also described are engineered cells expressing the fusion protein, optionally include one or more additional metabolic pathway transgene(s), methanol metabolic pathway genes, target product pathway genes, cell culture compositions including the cells, methods for promoting production of the target product or intermediate thereof from the cells, compositions including the target product or intermediate, and products made from the target product or intermediate.

US Patent:

20170247709, Aug 31, 2017

Filed:

Oct 11, 2016

Appl. No.:

15/290895

Inventors:

- San Diego CA, US
Mark J. BURK - San Diego CA, US
Robin E. OSTERHOUT - San Diego CA, US
Priti PHARKYA - San Diego CA, US
Jingyi LI - Carlsbad CA, US

International Classification:

C12N 15/52
C12P 7/18
C12N 1/20
C12N 1/16
C12N 1/14

Abstract:

Provided herein are non-naturally occurring eukaryotic organisms that can be engineered to produce and increase the availability of cytosolic acetyl-CoA. Also provided herein are non-naturally occurring eukaryotic organisms having a 1,3-butanediol (1,3-BDO) pathway. and methods of using such organisms to produce 1,3-BDO.

US Patent:

20160237410, Aug 18, 2016

Filed:

Oct 3, 2014

Appl. No.:

15/027169

Inventors:

- San Diego CA, US
Michael Patrick Kuchinskas - San Diego CA, US
Jingyi Li - San Diego CA, US
Harish Nagarajan - San Diego CA, US
Priti Pharkya - San Diego CA, US

International Classification:

C12N 9/04
C12P 7/24

Abstract:

Described herein are non-natural NAD+-dependent alcohol dehydrogenases (ADHs) capable of at least two fold greater conversion of methanol or ethanol to formaldehyde or acetaldehyde, respectively, as compared to its unmodified counterpart. Nucleic acids encoding the non-natural alcohol dehydrogenases, as well as expression constructs including the nucleic acids, and engineered cells comprising the nucleic acids or expression constructs are described. Also described are engineered cells expressing a non-natural NAD-dependent alcohol dehydrogenase, optionally include one or more additional metabolic pathway transgene(s), methanol metabolic pathway genes, target product pathway genes, cell culture compositions including the cells, methods for promoting production of the target product or intermediate thereof from the cells, compositions including the target product or intermediate, and products made from the target product or intermediate.

US Patent:

20140322779, Oct 30, 2014

Filed:

Nov 12, 2012

Appl. No.:

14/357497

Inventors:

- San Diego CA, US
Mark J. Burk - San Diego CA, US
Robin E. Osterhout - San Diego CA, US
Priti Pharkya - San Diego CA, US
Jingyi Li - San Diego CA, US

International Classification:

C12P 7/18

US Classification:

435158, 4352542, 435471, 43525422, 43525421

Abstract:

Provided herein are non-naturally occurring eukaryotic organisms that can be engineered to produce and increase the availability of cytosolic acetyl-CoA. Also provided herein are non-naturally occurring eukaryotic organisms having a 1,3-butanediol (1,3-BDO) pathway, and methods of using such organisms to produce 1,3-BDO.